Avacopan (English Wikipedia)

Analysis of information sources in references of the Wikipedia article "Avacopan" in English language version.

refsWebsite

Global rank English rank

15web.archive.org

1^st place

4europa.eu

68^th place

117^th place

4fda.gov

447^th place

338^th place

2tga.gov.au

3,984^th place

2,622^nd place

2chemocentryx.com

low place

1hres.ca

low place

1medicines.org.uk

3,823^rd place

2,387^th place

1nih.gov

4^th place

1handle.net

102^nd place

76^th place

chemocentryx.com

ir.chemocentryx.com

"ChemoCentryx Announces Approval in Japan of Tavneos (Avacopan) for the Treatment of ANCA-Associated Vasculitis". ChemoCentryx, Inc. (Press release). 27 September 2021. Archived from the original on 9 October 2021. Retrieved 11 October 2021.
"ChemoCentryx Announces FDA Approval of Tavneos (avacopan) in ANCA-Associated Vasculitis". ChemoCentryx, Inc. (Press release). 8 October 2021. Archived from the original on 8 October 2021. Retrieved 11 October 2021.

europa.eu

ema.europa.eu

"Tavneos EPAR". European Medicines Agency. 10 November 2021. Archived from the original on 17 March 2022. Retrieved 24 April 2022. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
"Tavneos: Pending EC decision". European Medicines Agency. 11 November 2021. Archived from the original on 12 November 2021. Retrieved 12 November 2021. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
"First-in-class medicine recommended for treatment of rare blood vessel inflammation". European Medicines Agency (Press release). 12 November 2021. Archived from the original on 12 November 2021. Retrieved 12 November 2021.

ec.europa.eu

"Tavneos Product information". Union Register of medicinal products. Archived from the original on 4 March 2023. Retrieved 3 March 2023.

fda.gov

accessdata.fda.gov

"Drug Approval Package: Tavneos". U.S. Food and Drug Administration (FDA). 4 November 2021. Archived from the original on 7 May 2022. Retrieved 7 May 2022.
"Center for Drug Evaluation and Research - Approval Package for: Application Number: 214487Orig1s000" (PDF). U.S. Food and Drug Administration (FDA). 7 October 2021. Archived (PDF) from the original on 7 May 2022.

fda.gov

Advancing Health Through Innovation: New Drug Therapy Approvals 2021 (PDF). U.S. Food and Drug Administration (FDA) (Report). 13 May 2022. Archived from the original on 6 December 2022. Retrieved 22 January 2023. This article incorporates text from this source, which is in the public domain.
"Drug Trials Snapshot: Tavneos". U.S. Food and Drug Administration (FDA). 7 October 2021. Archived from the original on 23 July 2023. Retrieved 23 July 2023. This article incorporates text from this source, which is in the public domain.

handle.net

hdl.handle.net

World Health Organization (2016). "International nonproprietary names for pharmaceutical substances (INN): recommended INN: list 76". WHO Drug Information. 30 (3). hdl:10665/331020.

hres.ca

hpr-rps.hres.ca

"Summary Basis of Decision - Tavneos". Health Canada. 28 July 2022. Archived from the original on 29 September 2022. Retrieved 29 September 2022.

medicines.org.uk

"Tavneos (Avacopan) Summary of Product Characteristics (SmPC)". emc. 26 May 2022. Archived from the original on 24 July 2023. Retrieved 23 July 2023.

nih.gov

dailymed.nlm.nih.gov

"Tavneos- avacopan capsule". DailyMed. Archived from the original on 1 November 2021. Retrieved 31 October 2021.

tga.gov.au

"Archived copy". Archived from the original on 2 January 2024. Retrieved 2 January 2024.{{cite web}}: CS1 maint: archived copy as title (link)
"Tavneos (Vifor Pharma Pty Ltd)". Therapeutic Goods Administration (TGA). 16 February 2023. Archived from the original on 27 March 2023. Retrieved 29 April 2023.

web.archive.org

"Archived copy". Archived from the original on 2 January 2024. Retrieved 2 January 2024.{{cite web}}: CS1 maint: archived copy as title (link)
"Tavneos (Vifor Pharma Pty Ltd)". Therapeutic Goods Administration (TGA). 16 February 2023. Archived from the original on 27 March 2023. Retrieved 29 April 2023.
"Summary Basis of Decision - Tavneos". Health Canada. 28 July 2022. Archived from the original on 29 September 2022. Retrieved 29 September 2022.
"Tavneos (Avacopan) Summary of Product Characteristics (SmPC)". emc. 26 May 2022. Archived from the original on 24 July 2023. Retrieved 23 July 2023.
"Tavneos- avacopan capsule". DailyMed. Archived from the original on 1 November 2021. Retrieved 31 October 2021.
"Tavneos EPAR". European Medicines Agency. 10 November 2021. Archived from the original on 17 March 2022. Retrieved 24 April 2022. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
"ChemoCentryx Announces Approval in Japan of Tavneos (Avacopan) for the Treatment of ANCA-Associated Vasculitis". ChemoCentryx, Inc. (Press release). 27 September 2021. Archived from the original on 9 October 2021. Retrieved 11 October 2021.
"ChemoCentryx Announces FDA Approval of Tavneos (avacopan) in ANCA-Associated Vasculitis". ChemoCentryx, Inc. (Press release). 8 October 2021. Archived from the original on 8 October 2021. Retrieved 11 October 2021.
"Drug Approval Package: Tavneos". U.S. Food and Drug Administration (FDA). 4 November 2021. Archived from the original on 7 May 2022. Retrieved 7 May 2022.
Advancing Health Through Innovation: New Drug Therapy Approvals 2021 (PDF). U.S. Food and Drug Administration (FDA) (Report). 13 May 2022. Archived from the original on 6 December 2022. Retrieved 22 January 2023. This article incorporates text from this source, which is in the public domain.
"Center for Drug Evaluation and Research - Approval Package for: Application Number: 214487Orig1s000" (PDF). U.S. Food and Drug Administration (FDA). 7 October 2021. Archived (PDF) from the original on 7 May 2022.
"Drug Trials Snapshot: Tavneos". U.S. Food and Drug Administration (FDA). 7 October 2021. Archived from the original on 23 July 2023. Retrieved 23 July 2023. This article incorporates text from this source, which is in the public domain.
"Tavneos: Pending EC decision". European Medicines Agency. 11 November 2021. Archived from the original on 12 November 2021. Retrieved 12 November 2021. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
"First-in-class medicine recommended for treatment of rare blood vessel inflammation". European Medicines Agency (Press release). 12 November 2021. Archived from the original on 12 November 2021. Retrieved 12 November 2021.
"Tavneos Product information". Union Register of medicinal products. Archived from the original on 4 March 2023. Retrieved 3 March 2023.